Max Masucci
Stock Analyst at TD Cowen
(0.20)
# 4,346
Out of 5,006 analysts
22
Total ratings
16.67%
Success rate
-30.77%
Average return
Main Sectors:
Stocks Rated by Max Masucci
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BRKR Bruker | Maintains: Hold | $74 → $72 | $36.46 | +97.48% | 1 | Aug 7, 2024 | |
| BLFS BioLife Solutions | Maintains: Outperform | $29 → $25 | $26.52 | -5.73% | 1 | Aug 9, 2023 | |
| GH Guardant Health | Maintains: Outperform | $70 → $53 | $63.38 | -16.38% | 1 | Feb 24, 2023 | |
| HOLX Hologic | Maintains: Outperform | $86 → $95 | $67.34 | +41.08% | 2 | Feb 2, 2023 | |
| QTRX Quanterix | Downgrades: Market Perform | $38 → $18 | $5.88 | +206.12% | 2 | Aug 9, 2022 | |
| BDSX Biodesix | Initiates: Outperform | n/a | $7.54 | - | 2 | Apr 20, 2022 | |
| EVO Evotec SE | Initiates: Outperform | n/a | $3.99 | - | 1 | Nov 29, 2021 | |
| NAUT Nautilus Biotechnology | Initiates: Outperform | n/a | $0.87 | - | 1 | Nov 2, 2021 | |
| MXCT MaxCyte | Initiates: Outperform | n/a | $1.65 | - | 1 | Aug 24, 2021 | |
| CTKB Cytek Biosciences | Initiates: Outperform | n/a | $4.02 | - | 1 | Aug 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $3.69 | - | 1 | Aug 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $5.65 | - | 1 | Jul 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $460 → $470 | $101.02 | +365.25% | 4 | Apr 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $10.90 | +129.36% | 1 | Apr 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $145 | $57.63 | +151.61% | 2 | Oct 28, 2020 |
Bruker
Aug 7, 2024
Maintains: Hold
Price Target: $74 → $72
Current: $36.46
Upside: +97.48%
BioLife Solutions
Aug 9, 2023
Maintains: Outperform
Price Target: $29 → $25
Current: $26.52
Upside: -5.73%
Guardant Health
Feb 24, 2023
Maintains: Outperform
Price Target: $70 → $53
Current: $63.38
Upside: -16.38%
Hologic
Feb 2, 2023
Maintains: Outperform
Price Target: $86 → $95
Current: $67.34
Upside: +41.08%
Quanterix
Aug 9, 2022
Downgrades: Market Perform
Price Target: $38 → $18
Current: $5.88
Upside: +206.12%
Biodesix
Apr 20, 2022
Initiates: Outperform
Price Target: n/a
Current: $7.54
Upside: -
Evotec SE
Nov 29, 2021
Initiates: Outperform
Price Target: n/a
Current: $3.99
Upside: -
Nautilus Biotechnology
Nov 2, 2021
Initiates: Outperform
Price Target: n/a
Current: $0.87
Upside: -
MaxCyte
Aug 24, 2021
Initiates: Outperform
Price Target: n/a
Current: $1.65
Upside: -
Cytek Biosciences
Aug 17, 2021
Initiates: Outperform
Price Target: n/a
Current: $4.02
Upside: -
Aug 9, 2021
Initiates: Outperform
Price Target: n/a
Current: $3.69
Upside: -
Jul 20, 2021
Initiates: Outperform
Price Target: n/a
Current: $5.65
Upside: -
Apr 28, 2021
Maintains: Buy
Price Target: $460 → $470
Current: $101.02
Upside: +365.25%
Apr 15, 2021
Initiates: Buy
Price Target: $25
Current: $10.90
Upside: +129.36%
Oct 28, 2020
Maintains: Buy
Price Target: $120 → $145
Current: $57.63
Upside: +151.61%